Fed Circuit backs Eli Lilly in Apotex’s appeal over failed Alimta NDA
The US Court of Appeals for the Federal Circuit yesterday, December 21, upheldEli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
8 January 2026 Important questions about when companies must act on suspicions of theft and whether damages can stack with injunctions were raised in a dispute that has already sent ripples across med tech.
8 January 2026 Crop science division alleges that vaccine developers used patented mRNA stability technology in shots that earned them around $140 billion in global sales.
6 January 2026 The new recruits from a boutique Boston firm enables Merchant to expand and strengthen its tech and life sciences offering in the innovation hub.
